Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label phase II study

American Journal of Respiratory and Critical Care Medicine

Volumn 159, Issue 4 I, 1999, Pages 1061-1069

  Raghu, Ganesh ^a,b   Johnson, W Craig ^a   Lockhart, Diane ^a   Mageto, Yolanda ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; PENICILLAMINE; PIRFENIDONE; PREDNISONE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERPIGMENTATION; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCLE WEAKNESS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME;

EID: 0032926937     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.159.4.9805017     Document Type: Article

References (33)

1. Meier-Sydow, J., S. M. Weiss, R. Buhl, M. Rust, and G. Raghu. 1994. Idiopathic pulmonary fibrosis: current clinical concepts and challenges in management. Semin. Respir. Crit. Care Med. 15:77-96.
2. Park, D. J., and G. Raghu. Idiopathic pulmonary fibrosis. In W. N. Kelley, editor. Textbook of Internal Medicine, 3rd ed. Lippincott-Raven, New York. 1996.
3. Lynch, J. P., and G. Toews. 1997. Idiopathic pulmonary fibrosis. In Elias Fishman and Kaiser Grippi, editors. Pulmonary Diseases and Disorders, 3rd ed. McGraw-Hill.
4. Katzenstein, A. A., and J. L. Myers. 1998. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. Rev. Respir. Crit. Care Med. 157:1301-1315.
5. Izumi, T., S. Nagai, Y. Kondo, and M. Tamura. 1993. Ten-year follow-up of 222 patients with idiopathic pulmonary fibrosis - a nation-wide survey report in Japan (abstract). Am. Rev. Respir. Dis. 145:A218.
6. Turner-Warwick, M., B. Burrows, and A. Johnson. 1980. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 35:171-180.
7. Crystal, R. G., P. B., Bitterman, S. I. Rennard, et al. 1984. Interstitial lung disease of unknown cause - disorders characterized by chronic inflammation of the lower respiratory tract. N. Engl. J. Med. 310:154-166.
8. DuBois, R. M. 1990. Cryptogeic fibrosing alveolitis. In R. A. L. Brewis, G. J. Gibson, and D. M. Geddes, editors. Respiratory Medicine. Baillere Tindall, London. 1088-1103.
9. Coultas, D. B., R. E. Zumwalt, W. C. Black, and R. E. Sobonya. 1994. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 150:967-972.
10. Raghu, G. 1987. Idiopathic pulmonary fibrosis: a rational clinical approach. Chest 92:148-154.
11. Rudd, R. M., P. I., Haslam, and M. Turner-Warwick. 1981. Cryptogenic fibrosing alveolitis: relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am. Rev. Respir. Dis. 124:1-8.
12. Hunninghake, G. W., and A. R. Kalica. 1995. Approaches to the treatment of pulmonary fibrosis: workshop summary. Am. J. Respir. Crit. Care Med. 151:915-918.
13. Lynch, J. P., and W. J. McCune. 1997. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am. J. Respir. Crit. Care Med. 155:395-429.
14. Iyer, S. N., J. S. Wild, M. J. Schiedt, D. M. Hyde, S. B. Margolin, and S. N. Giri. 1995. Dietary intake of pirfenidone ameliorates bleomycin-induced fibrosis in hamsters. J. Lab. Clin. Med. 125:779-785.
15. Lurton, J. M., T. Trejo, A. S. Narayanan, and G. Raghu. 1996. Pirfenidone inhibits the stimulatory effects of profibrotic cytokines on human lung fibroblasts in vitro (abstract). Am. J. Respir. Crit. Care Med. 153:A403.
16. Raghu, G. 1995. Interstitial lung disease: a diagnostic approach. Am. J. Respir. Crit. Care Med. 151:909-914.
17. American Thoracic Society. 1991. Lung function testing: selection of reference values and interpretative strategics. Am. Rev. Respir. Dis. 144:1202-1218.
18. Breslow, N. E., and N. E. Day. 1987. Statistical Methods in Cancer Research, Vol. II: The Design and Analysis of Cohort Studies. International Agency for Research on Cancer, Lyon, France.
19. Raghu, G., W. J. Depaso, K. Cain, S. P. Hammar, C. E. Wetzel, D. F. Dreis, et al. 1991. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 144:291-296.
20. Johnson, M. A., S. Swan, N. J. C. Snell, A. J. Nunn, J. H. Darbyshire, and M. Turner-Warwick. 1989. Randomized, controlled trial comparing prednisolone alone with cyclophosphamide and low dose predniso lone in combination in cryptogenic fibrosing alveolilis. Thorax 44: 280-288.
21. Erbes, R., and G. Schabert. 1997. Lung function tests in patients with IPF: are they helpful for predicting outcome? Chest 111:51-57.
22. Hanson, D., R. H. Winterbauer, S. H. Kirtland, and R. Wu. 1995. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 108:305-310.
23. Carrington, C. B., E. A. Gaensler, R. E. Coutu, et al. 1978. Natural history and treated course of usual and desquamative interstitial pneumonia, N. Engl. J. Med. 298:801-809.
24. Gulsvik, A., A. Kjelsberg, A. Bergmann, and S. S. Froland. 1986. High dose intravenous methylprednisolone pulse therapy as initial treatment in cryplogenic fibrosing alveolitis: a pilot study. Respiration 50: 252.
25. Meier Sydow, J., M. Rust, and H. Kroneneberger. 1979. Long-term follow-up of lung function parameters in patients with idiopathic pulmonary fibrosis treated with prednisone and azathioprine or D-penicillamine. Prax Pneumol. 33:680-688.
26. Cherniack, R. M., R. G. Crystal, and A. R. Kalica. 1991. Current concepts in idiopathic pulmonary fibrosis: a road map for the future. NHLBI Workshop Summary. Am. Rev. Respir. Dis. 143:680-683.
27. Raghu, G., and M. Kinsella. 1992. Cytokine effects on extracellular matrix. In J. Kelly, editor. Cytokines in the Lung, Vol. 61. In C. Lenfant, executive editor. Lung Biology in Health and Disease. Marcel Dekker, New York. 491-543.
28. Raghu, G., Y. Chen, V. Rusch, and P. S. Rabinovitch. 1998. Differential proliferation of cultured cells from normal and fibrotic human lungs. Am. Rev. Respir. Dis. 138:703-708.
29. Rochester, C. L., and J. A. Elias. 1993. Cytokines and cytokine networking in the pathogenesis of interstitial and fibrotic lung disorders. 14: 389-416.
30. Raghu, G., S. Masta, D. Meyers, and A. S. Narayanan. 1989. Collagen synthesis by normal and fibrotic human lung fibroblasts and the effect of transforming growth factor-β. Am. Rev. Respr. Dis. 140:95-100.
31. Douglas, W. W., J. H. Ryu, J. Swensen, P. Offord, D. R. Schroeder, et al. 1998. Colchicineversus prednisone in the treatment of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 158:220-225.
32. Narayanan, A. S., J. Whithey, A. Souza, and G. Raghu. 1992. Effect of γ-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 101:1326-1331.
33. Katzenstein, A. A., and R. F. Fiorelli. 1994. Nonspecific interstitial pneumonia/fibrosis: histologic features and clinical significance. Am. J. Surg. Pathol. 18:136-147.